

IN THE CLAIMS:

Please rewrite the current versions of claims 13, 16, and 17 as follows. Pursuant to 37 C.F.R. § 1.121, The following is a clean version of the rewritten claims. A marked-up version of the rewritten claims is attached on a separate sheet.

13. (Once Amended) A staphylokinase derivative having essentially the amino acid sequence as depicted in figure 3 (SEQ ID NO: 10) in which one or more encircled or boxed amino acids have been replaced by another amino acid thus reducing the absorption of SakSTAR-specific antibodies from plasma of patients treated with staphylokinase and further incorporating one or more polyethylene glycol groups.

16. (Once Amended) Staphylokinase derivatives SakSTAR(K35X, G36X, E65X, K74X, E80X, D82X, K102X, E108X, K109X, K121X, K130X, K135X, K136X, +137X) having the amino acid sequence as depicted in Figure 1 (SEQ ID NO: 10) in which the amino acids Lys in position 35, Gly in position 36, Glu in position 65, Lys in position 74, Glu in position 80, Asp in position 82, Lys in position 102, Glu in position 108, Lys in position 109, Lys in position 121, Lys in position 130, Lys in position 135 and/or Lys in position 136 have been replaced with other amino acids and/or in which one amino acid has been added at the COOH-terminus, thus altering the immunogenicity after administration in patients, and further incorporating at least one polyethylene glycol group.

17. (Once Amended) Staphylokinase derivatives listed in Tables 1, 2, 3, 4, 5, 6, 7 and 8, having the amino acid sequence depicted in figure 3 (SEQ ID NO: 10) in which the boxed or encircled amino acids have been replaced by other amino acids thus reducing the absorption of SakSTAR-specific antibodies from plasma of patients treated with staphylokinase, without

reducing the specific activity, the derivative further incorporating at least one polyethylene glycol group.

IN THE DRAWINGS:

Copies of Figure 1 and Figure 3 have been supplied with the amendment (the addition of a SEQ ID NO) indicated in red. No new matter is added by these amendments. The correction of Figure 1 and Figure 3 will be made formally when formal figures are filed at a later date.